Wed.Oct 02, 2024

article thumbnail

Cloud Computing in the Pharmaceutical Industry

Pharmaceutical Technology

Discover the leading providers of cloud computing in the pharmaceutical industry. Download the free Buyer's Guide for full contact details.

130
130
article thumbnail

How Roche plans to fill a projected $8B sales gap

Bio Pharma Dive

Biosimilar competition to aging blockbusters will erode a large chunk of the pharma giant’s top line over the next few years.

Sales 269
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exscientia outline robot and AI use in drug discovery workflow

Pharmaceutical Technology

Exscientia detailed how its robotics lab in Oxfordshire, UK is increasing productivity and efficiency in developing new molecules at ELRIG 2024.

article thumbnail

Your Smartphone Could Soon Measure Your Blood Pressure With Just a Touch

AuroBlog - Aurous Healthcare Clinical Trials blog

(akaratwimages/Canva) High blood pressure (or hypertension) increases the risk of health problems such as heart or kidney failure, but goes undiagnosed in millions of people.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

LoQus23 secures $43m to advance Huntington’s Disease therapy

Pharmaceutical Technology

The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.

article thumbnail

With $115M more, Triveni accelerates immune drug work

Bio Pharma Dive

The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.

Drugs 184

More Trending

article thumbnail

Jan Aushadhi Kendras report 6.7 per cent growth in sales in August

AuroBlog - Aurous Healthcare Clinical Trials blog

The Jan Aushadhi Kendras (JAKs) under the flagship scheme of the Department of Pharmaceuticals (DoP), Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), has reported a growth of 6.

Sales 170
article thumbnail

Gilead agrees to license new HIV drug in low-income countries

Bio Pharma Dive

The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease but limited resources.

Licensing 157
article thumbnail

Shattuck Labs stock craters following pipeline and job cuts

Pharmaceutical Technology

The cash-saving measures come after interim analysis showed the company’s lead cancer drug only showed modest improvement in survival.

Drugs 130
article thumbnail

Blue Shield of California sidesteps PBMs with new Humira biosimilar deal

Bio Pharma Dive

It’s the first time, according to the insurer, that this type of model has been used to bring a Humira biosimilar to market, and it yields a much lower cost than both the brand-name version of the drug and biologic copycats.

Branding 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec

Pharmaceutical Technology

Focus is turning to the development of peptide analogs of antibody-derived radiotherapeutics, according to Dr. Dave Madge.

Antibody 130
article thumbnail

Lilly plans $4.5B ‘foundry’ for advanced drug manufacturing

Bio Pharma Dive

With its latest investment, Lilly is looking toward medicines of the future and new methods to produce them.

article thumbnail

Triveni scores $115m to expand immunology pipeline

Pharmaceutical Technology

The Series B funds will expedite pipeline expansion and cover a clinical proof-of-concept study for TRIV-573.

130
130
article thumbnail

Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med

Fierce Pharma

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.

Licensing 123
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Amgen to face investor lawsuit over $10.7bn tax liability disclosure

pharmaphorum

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.

122
122
article thumbnail

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility

Fierce Pharma

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31

article thumbnail

Blue Shield of California bypasses PBMs to slash Humira prices by 90%

pharmaphorum

In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%

Pharmacy 103
article thumbnail

J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study

Fierce Pharma

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.

Marketing 107
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Insilico Medicine reports positive results for idiopathic pulmonary fibrosis therapy

Pharma Times

ISM001-055 shows promise in improving lung function among patients

Medicine 146
article thumbnail

Amgen can't sidestep investor lawsuit over $10.7B tax bill

Fierce Pharma

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IR | New York District Judge John Cronan has rejected Amgen’s motion to dismiss an investor lawsuit—originally filed by a Michigan-based union pension fund—accusing the company of hiding a $10.7-billion tax bill from the public.

104
104
article thumbnail

Closed and Collaborative: Mergers, acquisitions, and partnerships in August 2024

pharmaphorum

Explore the mergers, acquisitions, and partnerships in August 2024. Discover how these collaborations are shaping the business landscape.

113
113
article thumbnail

Pharma Plant Sleuthing: 8 Ways to Find Manufacturing Capacity as an Outsider

Drug Patent Watch

As an outsider, finding out the manufacturing capacity of a given pharmaceutical manufacturing plant can be challenging due to the proprietary nature of such information. However, you can employ several strategies to gather relevant data: Example: Pfizer’s 2022 Annual Report states, “Our manufacturing facilities are located in 39 countries across 6 continents.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Revisionist history on healthcare at the VP debate

pharmaphorum

In the VP debate, Tim Walz and JD Vance were forceful, unexpectedly convivial, and fast and loose with the facts, particularly on healthcare.

104
104
article thumbnail

AlzeCure’s ACD856’s effects to be presented at Alzheimer’s conference

Pharma Times

Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid

117
117
article thumbnail

The patient will see you now: Why embracing discomfort could transform patient engagement

pharmaphorum

The patient will see you now: Why embracing discomfort could transform patient engagement Mike.

115
115
article thumbnail

New CTTI Project Aims to Offer Clarity Around Implementing Flexible Clinical Trial Approaches While Maintaining Data Quality

CTTI (Clinical Trials Transformation Initiative)

Implementing less rigid, more flexible approaches to clinical trials can increase patient and site access to research, improve participant satisfaction, facilitate real-world data use, enroll more diverse patient populations, and enable more generalizable trial results. Ultimately, these flexible trial approaches help sponsors bring new therapies to patients faster.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

FDA issues summary of grants, promotes rare disease research

pharmaphorum

FDA issues summary of grants, promotes rare disease research Nicole.

Research 111
article thumbnail

Navigating Privacy and Personalization in Pharma Advertising with Emily Keith

Fierce Pharma

Sitting down with Emily Keith, SVP at AdTheorent Health, at Digital Pharma East 2024, we explored the cutting-edge int | Sitting down with Emily Keith, SVP at AdTheorent Health, at Digital Pharma East 2024, we explored the cutting-edge intersection of healthcare, advertising and privacy.

65
article thumbnail

Indeterminate Change: FDA Releases Draft Guidance on Predetermined Change Control Plans for Medical Devices

FDA Law Blog

By Adrienne R. Lenz, Principal Medical Device Regulation Expert & Lisa M. Baumhardt, Senior Medical Device Regulation Expert & Gail H. Javitt — A recent draft guidance on predetermined change control plans (PCCP) for medical devices continues FDA’s effort to implement Section 515C of the Food and Drug Omnibus Reform Act of 2022 (FDORA), which Congress enacted to make it easier for manufacturers to make post-market device changes by avoiding the need for additional FDA authorization (se

article thumbnail

Phreesia on the power of personalization and a privacy-first model

Fierce Pharma

Founded in 2005, Phreesia provides cutting-edge technology that helps healthcare organizations engage patients more effe | Founded in 2005, Phreesia provides cutting-edge technology that helps healthcare organizations engage patients more effectively, empowering them to take an active role in their care. By enhancing patients’ understanding, skills, and confidence, the company is revolutionizing the way healthcare content is delivered.

52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.